Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

JNJ Johnson and Johnson

162,99

0,00 (0,00%)

13 Mar 2025 - Fechado

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

02/07/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Joseph J. Wolk

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025

Click aqui para mais gráficos Johnson and Johnson.

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025

Click aqui para mais gráficos Johnson and Johnson.

Notícias Johnson and Johnson

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Quarta, 12 de Março de 2025 (2 dias atrás) • Edgar (US Regulatory)

Form ARS - Annual Report to Security Holders
Quarta, 12 de Março de 2025 (2 dias atrás) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Quarta, 12 de Março de 2025 (2 dias atrás) • Edgar (US Regulatory)

Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
Segunda, 10 de Março de 2025 (4 dias atrás) • PR Newswire (Canada)

Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
Segunda, 10 de Março de 2025 (4 dias atrás) • PR Newswire (US)

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Sábado, 8 de Março de 2025 (6 dias atrás) • PR Newswire (US)

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Sexta, 7 de Março de 2025 (6 dias atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 6 de Março de 2025 (1 semana atrás) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 26 de Fevereiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 8-A12B - Registration of securities [Section 12(b)]
Quarta, 26 de Fevereiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quarta, 26 de Fevereiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Terça, 25 de Fevereiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Mais Notícias de Johnson and Johnson

MTI Wireless Edge (PK)

ETF Series Solut

H and E Equipment Services

Aspen Pharmacare (PK)

Citius Oncology

ETHJ25 - Abril 2025

Wuxi Biologics Cayman (PK)

Plum Acquisition Corpora...

American Lithium

Sky Petroleum (CE)

Shellron Capital

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições